Factbox: Drugs to watch at Roche, Sanofi and GSK

(Reuters) – GlaxoSmithKline, Roche and Sanofi all hold investor days this week. Below are three new drugs to watch from each company, with consensus annual sales in 2020, according to Thomson Reuters Cortellis.

*GlaxoSmithKline:

– Nucala, severe asthma injection, $756 million

– Shingrix, shingles vaccines, $594 million

– sirukumab, rheumatoid arthritis (with JJ), $980 million

*Roche

– ocrelizumab, multiple sclerosis, $1,051 million

– atezolizumab, cancer, $3,188 million

– ACE-910, haemophilia, $721 million

*Sanofi:

– dupilumab, asthma/dermatitis (with Regeneron), $1,409 million

– sarilumab, rheumatoid arthritis (with Regeneron), $516 million

– LixiLan, diabetes, $815 million

(Reporting by Ben Hirschler. Editing by Jane Merriman)

• Disease Medical Conditions
• Health
• GlaxoSmithKline
• Roche
• rheumatoid arthritis